Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2541 - Long-term duration of axitinib treatment in advanced renal cell carcinoma


09 Oct 2016


Poster display


Brian Rini


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


B.I. Rini1, V. Grünwald2, E. Jonasch3, M.N. Fishman4, Y. Tomita5, M..D. Michaelson6, J. Tarazi7, L. Cisar8, A.H. Blair7, B. Rosbrook7, T. Hutson9

Author affiliations

  • 1 Department Of Hematology And Oncology, Cleveland Clinic Taussig Cancer Institute, 44195 - Cleveland/US
  • 2 Clinic For Hematology, Hemostasis, Oncology, And Stem Cell Transplantation, Medical School Hannover, 30627 - Hannover/DE
  • 3 Genitourinary Oncology, MD Anderson Cancer Center, TX 77030 - Houston/US
  • 4 Medical Oncology, H. Lee Moffitt Cancer Center University of South Florida, Tampa/US
  • 5 Development Of Urology, Niigata University Graduate School of Medical and Dental Sciences., Niigata/JP
  • 6 Medical Oncology, Massachusetts General Hospital, Boston/US
  • 7 Oncology, Pfizer Inc, San Diego/US
  • 8 Oncology, Pfizer Inc, New York/US
  • 9 Gu Medical Oncology, Texas Oncology - Baylor Sammons Cancer Center, 75246 - Dallas/US


Abstract 2541


Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors approved globally in advanced renal cell carcinoma (aRCC). A subset of patients (pts) treated with axitinib achieve long-term disease control. This analysis characterized the duration of treatment (DT) and clinical outcome of pts with aRCC who achieved a DT >18 months on axitinib therapy.


A retrospective analysis of data from 402 treatment-naïve pts with aRCC treated with axitinib in phase II (NCT00835978) or III (NCT00920816) clinical trials was conducted. Data on DT, objective response rate (ORR) per RECIST v1 criteria, and early tumor shrinkage (defined as ≥10% shrinkage at first scan) were compared between pts who had DT >18 months (longer DT) vs pts who had DT ≤ 18 months (shorter DT). Analysis was conducted to identify baseline characteristics associated with longer DT.


Of the 402 pts, 152 (37.8%) had longer DT and 250 (62.2%) had shorter DT. Overall, 119 (29.6%) had DT > 2 years, 71 (17.7%) had DT > 3 years, and 28 (7.0 %) had DT > 4 years. The median (range) DT was 34.7 (18.4–60.1) months for longer DT vs 6.5 (0.1–17.7) months for shorter DT. ORR was 75% for longer DT vs 24.4% for shorter DT (difference, 50.6%; 95% CI 41.9–59.3%; p  13 g/dL or female: > 11.5), no bone or liver metastases, and baseline tumor burden below overall median sum of longest diameter (96 mm) were associated with longer DT.


Among aRCC patients treated with first-line axitinib, a substantial proportion of patients remain on therapy for a prolonged period of time. Longer axitinib treatment duration (>18 months) is associated with increased ORR and increased frequency of early tumor shrinkage.

Clinical trial identification

NCT00835978 and NCT00920816

Legal entity responsible for the study

Pfizer, Inc.


Pfizer, Inc.


B.I. Rini, E. Jonasch: has received research funding and consulting fees from Pfizer. V. Grünwald: has received consulting fees and honoraria from Pfizer, Roche, GSK and Novartis, research funding from Wyeth Oncology, and a lecture honorarium from Bayer. M.N. Fishman: reports research funding and honoraria from Aveo, Altor Biosciences, Bayer, Genentech, GSK, and Pfizer; research funding from BMS, Eisai and Exelixis; honoraria from Alkermes and Prometheus. Y. Tomita: served as a consultant for Novartis and Ono, and received speaker honoraria and grants from Pfizer, Bayer and Novartis, grants from AstraZeneca and Astellas, and speaker honoraria from GlaxoSmithKline. M.D. Michaelson: received research funding and consulting fees from Pfizer, Novartis, and Exelixis. J. Tarazi, L. Cisar, A.H. Blair, B. Rosbrook: is a full-time employee of and declares stocks from Pfizer. T. Hutson: has received consulting fees and research funding from Pfizer, Exelexis, Eisai, Novartis, and BMS.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings